National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$39.95
add to cart

Rights & Permissions

topleft topright

To Err Is Human: Building a Safer Health System (2000)
Institute of Medicine (IOM)

Citation Manager

. "C Literature Summary." To Err Is Human: Building a Safer Health System. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
253
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Page 253

(table continued from previous page)

Reference

Results

Definition(s)

Causes/Types of Error

Cost (continued)

     

Johnson and Bootman, 1995
Drug-related morbidity and mortality

Drug-related morbidity and mortality costs an estimated $76.6 billion in the ambulatory setting in the United States. The panel members estimated that 40% of patients who receive drug therapy would have some form of DRP.

Drug-related problem—"an event or circumstance that involves a patient's drug treatment that actually, or potentially, interferes with the achievement of an optimal outcome."

 

Schneider et al., 1995
Cost of medication-related problems at a university hospital

349 clinical outcomes associated with medical related problems (MRPs) (average of approximately 3 outcomes per patient) were detected. For the 1,911 ADRs and medication errors reported through the voluntary reporting system in 1994, the estimated annual cost was just under $1.5 million.

   

Bloom, 1988
Cost of treating arthritis and NSAID-related gastrointestinal side-effects

In 1983, an estimated $3.9 million was spent on treating preventable gastrointestinal adverse drug reactions to NSAIDs.

Gastrointestinal adverse drug reaction—"any claim for payment accompanied by a diagnosis of peptic ulcer, gastritis/duodenitis, other disorders of the stomach or duodenum, gastrointestinal symptoms, or a pharmacy claim for an H2-recepter antagonist, sucralfate or antacid, which occurred during the arthritis treatment study period.

 
Page
253